Autobio Diagnostics and China National Medical Device Form Strategic Partnership
Autobio Diagnostics Co., Ltd (SHA: 603658), a Chinese in-vitro diagnostics company, has entered into a...
Valgen Secures NMPA Approval for China’s First Transcatheter Mitral Valve Clamp System
Hangzhou-based Valgen Holding Corporation has received market approval from the National Medical Products Administration (NMPA)...
Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market
Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...
Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD...
AbbVie to Acquire ImmunoGen for USD 10.1 Billion, Expanding Oncology Portfolio
AbbVie (NYSE: ABBV) has reached an agreement to acquire fellow U.S. biotech ImmunoGen (NASDAQ: IMGN)...
Akeso Biopharma Files New Indication for Penpulimab in First-Line NPC Treatment
Akeso Biopharma (HKG: 9926) has announced a new indication filing for its programmed death-1 (PD-1)...
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80...
Shanghai Junshi’s Loqtorzi Enters Australian Market Approval Process for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the Therapeutic Goods...
CARsgen Therapeutics Secures U.S. FDA Approval for CT071 Clinical Trials in Multiple Myeloma
CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received...
Lepu Biotechnology’s MRG003 Gains Fast-Track Status from U.S. FDA for Nasopharyngeal Carcinoma
Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced that its flagship product...
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover...
FDA Investigates Safety of China-Made Plastic Syringes Due to Quality Concerns
The US Food and Drug Administration (FDA) has issued a warning that it is investigating...
China’s State Council Unveils Comprehensive Plan to Boost Beijing’s Healthcare Sector
The State Council has unveiled a comprehensive “Work Plan” aimed at enhancing Beijing’s service industry...
Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System
Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical...
Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions
Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar...